Aurobindo Pharma Limited, a Hyderabad-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients (APIs), has received approval from Health Canada -- a department of the Canadian government with responsibility for national public health -- for its abbreviated new drug submission Terbinafine tablets in 125mg and 250mg strengths. This is Aurobindo's 5th product approval from the Canadian department.
Terbinafine (Terbinafine hydrochloride) tables 125mg and 250mg is the generic equivalent of Novartis Pharmaceutical Canada Inc's Lamisil tablets, indicated for the treatment of fungal infections of the skin and nails, according to a press release on Wednesday.